Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials.

Silva RB, Cheng B, Lee SM

Open source

DOI
10.1093/biomtc/ujag161
Published
2026 Jul 1
Container
Biometrics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/biomtc/ujag161,
  title = {Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials.},
  author = {Silva RB and Cheng B and Lee SM},
  year = {2026},
  journal = {Biometrics},
  doi = {10.1093/biomtc/ujag161},
  url = {https://doi.org/10.1093/biomtc/ujag161}
}

RIS

TY  - JOUR
TI  - Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials.
AU  - Silva RB
AU  - Cheng B
AU  - Lee SM
PY  - 2026
JO  - Biometrics
DO  - 10.1093/biomtc/ujag161
UR  - https://doi.org/10.1093/biomtc/ujag161
ER  - 

APA

RB, S., B, C., & SM, L. (2026). Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials.. Biometrics. https://doi.org/10.1093/biomtc/ujag161

Source records